Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raphamin for ARVI in Children (3-12 Years)
NCT06715891Phase 3Recruiting
- Sponsor
- Materia Medica Holding
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of raphamin in acute respiratory viral infection (ARVI), sponsored by Materia Medica Holding. Primary endpoint: Time to resolution of ARVI symptoms (PCR-confirmed) at 14 days. Started Nov 2024; status: recruiting.
02
Drugs
raphamin
03
Conditions
acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT06715891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715891.